Randomised clinical trial: Individualised vs. weight-based dosing of azathioprine in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 2, 2014, Pages 163-175

  Dassopoulos, T ^a   Dubinsky, M C ^b   Bentsen, J L ^c   Martin, C F ^d   Galanko, J A ^e   Seidman, E G ^f   Sandler, R S ^d   Hanauer, S B ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; PLACEBO; PREDNISONE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ADULT; ARTICLE; BLOOD CELL COUNT; BODY WEIGHT; BONE MARROW SUPPRESSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ERYTHEMA MULTIFORME; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER TOXICITY; MAINTENANCE DRUG DOSE; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEPSIS; UNSPECIFIED SIDE EFFECT; VIREMIA;

ADOLESCENT; ADULT; AZATHIOPRINE; BODY WEIGHT; CHILD; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PRODRUGS; THIOGUANINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890562279     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12555     Document Type: Article

References (18)

1. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M,. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;(1): CD000067.
2. Dignass A, Van Assche G, Lindsay JO, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
3. Talley NJ, Abreu MT, Achkar JP, et al,. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011; 106 (Suppl. 1): S2-25.
4. Ha C, Dassopoulos T,. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010; 4: 575-88.
5. Colombel JF, Ferrari N, Debuysere H, et al,. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
6. ® (azathioprine) product information. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2011/016324s034s035lbl.pdf.
7. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W,. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-87.
8. Belli DC, Seidman E, Bouthillier L, et al,. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988; 94: 603-10.
9. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD,. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
10. Dubinsky MC, Yang H, Hassard PV, et al,. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
11. Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML,. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol 2008; 6: 654-60.
12. Haines ML, Ajlouni Y, Irving PM, et al,. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1301-7.
13. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB,. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5: 209-14.
14. Leung Y, Sparrow MP, Schwartz M, Hanauer SB,. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis 2009; 3: 162-7.
15. Govani SM, Higgins PD,. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 2010; 4: 444-9.
16. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD,. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012; 6: 905-12.
17. Reinshagen M, Schutz E, Armstrong VW, et al,. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007; 53: 1306-14.
18. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH,. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-7.